Pharmacokinetics and pharmacodynamics of Phor21-βCG(ala), a lytic peptide conjugate

Journal of Pharmacy and Pharmacology

Volumn 60, Issue 11, 2008, Pages 1441-1448

  Jia, Lee ^a   Noker, Patricia E ^b   Piazza, Gary A ^b   Leuschner, Carola ^c   Hansel, William ^c   Gorman, Gregory S ^b   Coward, Lori U ^b   Tomaszewski, Joseph ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN DERIVATIVE; ANTINEOPLASTIC AGENT; LUCIFERASE; PEPTIDE; PHOR21 BETACG(ALA) PEPTIDE; PHOR21-BETACG(ALA) PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DOG; DRUG HYDROLYSIS; DRUG STABILITY; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PHARMACODYNAMICS; RAT; TANDEM MASS SPECTROMETRY; ANIMAL; AREA UNDER THE CURVE; BAGG ALBINO MOUSE; C57BL MOUSE; CELL PROLIFERATION; DRUG EFFECT; FISCHER 344 RAT; GENETIC TRANSFECTION; GENETICS; METASTASIS; PROSTATE TUMOR; SPECIES DIFFERENCE; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CACO-2 CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, LIQUID; DOGS; HUMANS; LUCIFERASES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM METASTASIS; PEPTIDES; PROSTATIC NEOPLASMS; RATS; RATS, INBRED F344; SPECIES SPECIFICITY; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; TRANSFECTION;

EID: 54949117958     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.60.11.0004     Document Type: Article

References (26)

1. Bodek, G., Rahman, N. A., Zaleska, M., Soliymani, R., Lankinen H., Hansel, W., Huhtaniemi, I., Ziecik, A. J. (2003) A novel approach of targeted ablation of mammary carcinoma cells through luteinizing hormone receptors using Hecate-CGbetat conjugate. Breast Cancer Res. Treat. 79: 1-10
2. Gawronska, B., Leuschner, C., Enright, F., Hansel, W. (2002) Effects of a lytic peptide conjugated to beta-hCG on ovarian cancer studies in vitro and in vivo. Gynecol. Oncol. 85: 45-52
3. Hansel, W. (2005) Targeting breast, prostate, ovarian, and testicular cancer through their hormone receptors. Biol. Reprod. 73: 850
4. Hansel, W., Leuschner, C., Gawronska, B., Enright, F. (2001) Targeted destruction of prostate cancer cells and xenografts by lytic peptide-βLH conjugates. Reprod. Biol. 1: 20-32
5. Hansel, W. Enright, F., Leuschner, C. (2007a) Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo. Mol. Cell. Endocrinol. 260-262: 183-189
6. Hansel, W., Leuschner, C., Enright, F. (2007b) Conjugates of lytic peptides and LHRH or βCG target and cause necrosis of prostate cancers and metastases. Mol. Cell. Endocrinol. 269: 26-33
7. Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., Thun, M. J. (2003) Cancer statistics. CA Cancer J. Clin. 53: 5-26
8. Jia, L., Liu, X. D. (2007) The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr. Drug Metab. 8: 822-829
9. Jia, L., Wong, H., Wang, Y., Garza, M., Weitman, S. (2003) Carbendazim: disposition, cellular permeability, metabolite identification and pharmacokinetic comparison with its nanoparticle. J. Pharm. Sci. 92: 161-172
10. Jia, L., Coward, L., Gorman, G. S., Noker, P. E., Tomaszewski, J. E. (2005a) Pharmacoproteomic effects of isoniazid, ethambutol, and N-Geranyl-N′-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv. J. Pharmacol. Exp. Ther. 315: 905-911
11. Jia, L., Tomaszewski, J., Hanrahan, C., Coward, L., Noker, P. E., Gorman, G. S., Nikonenko, B., Protopopova, M. (2005b) Pharmacodynamic and pharmacokinetic characteristics of SQ109, a new diamine-based antitubercular drug. Br. J. Pharmacol. 144: 80-87
12. Jia, L., Coward, L. C., Kerstner-Wood, C. D., Gorman, G. S., Noker, P. E., Kitada, S., Pellecchia, M. P., Reed, J. C. (2008a) Comparison of pharmacokinetics and metabolic profiling among Gossypol, Apogossypol and Apogossypol Hexaacetate. Cancer Chemother. Pharmacol. 61: 63-73
13. Jia, L., Schweikart, K., Tomaszewski, J., Page, J., Noker, P. E., Buhrow, S. A., Reid, J. M., Ames, M., Munn, D. (2008b) Toxicology and pharmacokinetics of 1-methyl-D-tryptophan: absence of toxicity due to saturating absorption. Food Chem. Toxicol. 46: 203-211
14. Johnstone, S.A., Gelmon, K., Mayer, L. D., Hancock, R. E., Bally, M. B. (2000) In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des. 15: 151-160
15. Leuschner, C., Hansel, W. (2004) Membrane disrupting lytic peptides for cancer treatments. Curr. Pharm. Des. 10: 2299-2310
16. Leuschner, C., Hansel, W. (2005) Targeting breast and prostate cancers through their hormone receptors. Biol. Reprod. 73: 860-865
17. Leuschner, C., Enright, F. M., Melrose, P. A., Hansel, W. (2001) Targeted destruction of androgen-sensitive and insensitive prostate cancer cells and xenografts through luteinizing hormone receptors. Prostate 46: 116-125
18. Leuschner, C., Enright, F., Gawronska, B., Hansel, W. (2003a) Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo. Breast Cancer Res. Treat. 78: 17-27
19. Leuschner, C., Enright, F., Gawronska, B., Hansel, W. (2003b) Targeted destruction of prostate cancer xenografts through luteinizing hormone releasing hormone receptors. Prostate. 56: 239-249
20. Liu, X. D., Jia, L. (2007) The conduct of drug metabolism studies considered good practice (I): analytical systems and in vivo studies. Curr. Drug Metab. 8: 815-821
21. Mathews, C. K., van Holde, K. E. (1991) Enzymes: biological catalysts. In: Mathews, C. K., van Holde, K. E (eds) Biochemistry. 2nd edn, Benjamin/Cummings, California, pp 339-380
22. Proskuryakov, M. T., Dubinkin, D. V. (1971) Nature of the trypsin-like activity of the blood. Biochem. Biophys. 76: 786-788
23. Rubio, N., Villacampa, M. M., Blanco, J. (1998) Traffic to lymph nodes of PC-3 tumor cells in nude mice visualized using the luciferase gene as a tumor cell marker. Lab. Invest. 78: 1315-1325
24. Rubio, N., Villacampa, N., Hilali, N. E., Blanco, J. (2000) Metastatic burden in nude mice organs measured using prostate tumor PC-3 cells expressing the luciferase gene as a quantifiable tumor cell marker. Prostate 44: 133-143
25. Zaleska, M., Bodek, G., Jana, B., Hansel, W., Ziecik, A. J. (2003) Targeted destruction of normal and cancer cells through lutropin/ choriogonadotropin receptors using Hecate-betaCG conjugate. Exp. Clin. Endocrinol. Diabetes 111: 146-153
26. Zaleska, M., Waclawik, A., Bodek, G., Zezula-Szpyra, A., Li, X., Janowski, T., Hansel, W., Rahman, N. A., Ziecik, A. J. (2004) Growth repression in diethylstilbestrol/dimethylbenz[a]anthracene-induced rat mammary gland tumor using Hecate CGbeta conjugate. Exp. Biol. Med. 229: 335-344